CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

This is a quarterly report (Form 10-Q) for Cryo-Cell International, Inc. for the period ended February 28, 2010. The company is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'elle). The company operates a facility in Oldsmar, Florida, and holds licensing agreements in various international markets including Mexico, Venezuela, China, and Germany.

Key Financial Metrics

Debt and Liquidity: The company has no long-term indebtedness as of April 14, 2010. However, it owes a remaining balance of $184,224 to Red Rock for the acquisition of Safti-Cell, payable in quarterly installments. The company maintains significant deferred revenue liabilities totaling approximately $12.77 million ($5.35 million current, $7.42 million long-term).

Material Changes vs. Prior Period

• Revenue: Total revenue decreased slightly by 0.4% ($18,157) compared to the prior year. This was driven by a 2% decrease in processing and storage fees, partially offset by a 15% increase in licensee income.
• Net Income: Net income declined by 42% ($234,742) to $319,234. The decline was primarily due to an 11% increase in marketing, general, and administrative expenses and a 103% increase in research and development expenses.
• Operating Cash Flow: Operating cash flow turned negative, using $62,063, compared to a positive $1,053,666 in the prior year. This shift was largely due to a $100,000 payment for a museum sponsorship and changes in working capital.
• Accounting Reclassifications: The company reclassified licensee income from "other income" to "revenue" to reflect its significance. Additionally, prior period errors regarding licensee income and foreign tax expenses were corrected, though these did not impact net income.

Outlook, Risks, and Management Commentary

Management Commentary: Management expects to increase marketing expenditures for the C'elle service. They anticipate funding future capital expenditures (approx. $500,000 over the next 12 months) with cash on hand and operating cash flows. The company believes its current liquidity is sufficient for the next 12 months but may seek financing if revenue growth does not materialize.

Risks and Contingencies:

• Internal Controls: The company previously identified a material weakness in internal controls regarding the accrual of licensee royalties. While remediation steps (restructuring agreements, adding staff) have been implemented, management concluded that disclosure controls remain ineffective as they have not been operating long enough to be deemed effective.
• Regulatory and Market Risks: Risks include increased government regulation of stem cell facilities, competition from public cord blood banks, and the uncertainty of market acceptance for new technologies like C'elle.
• Licensee Dependence: Revenue is dependent on the performance of international licensees. Deterioration in their financial condition could impact royalty collections.
• Warranty Reserves: The company maintains a reserve of approximately $10,395 for product warranty and Cryo-CellCares programs, which could increase if usage or failure rates rise.

Investor Verification Checklist

• Verify the effectiveness of the new internal controls over financial reporting regarding licensee royalty accruals.
• Monitor the trend of operating cash flows, which turned negative in Q1 2010, to ensure liquidity remains sufficient without new financing.
• Assess the impact of increased marketing and R&D spending on future profitability, given the decline in net income.
• Review the status of international licensing agreements and the collectibility of deferred revenue from foreign licensees.
• Confirm the timeline and potential impact of the new FASB Accounting Standard Update (ASU No. 2009-13) on revenue recognition for multiple-deliverable arrangements.